Nebivolol – New Cardioselective Beta Blocker
Nebivolol, (bystolic, nebilet, nebil) is a long acting cardioselective
at present licensed for the treatment of high blood pressure. Nebivolol,
(bystolic, nebilet, nebil) is accessible in market with names of Bystolic, Nebilet, Nebil.
It has mild vasodilating properties attributed to its interaction with the
L-arginine/nitric oxide pathway, a property not shared by other beta-blockers like Atenolol. So far
this has been demonstrated in volunteers and small numbers of patients.
If this mechanism is proven to result in improved medical outcomes, nebivolol,
(bystolic, nebilet, nebil) might be of worth in managing hypertensive individuals with endothelial
dysfunction eg those with diabetes mellitus or hypercholesterolaemia and in patients with Acute
Coronary Syndrom (ACS).
It is an effective antihypertensive agent. Short-term period up to 12 weeks.
published clinical research in sufferers with mild essential high blood pressure have shown that it
lowers sitting systolic and diastolic blood pressure to a similar extent as standard therapies
-atenolol, metoprolol, enalapril, lisinopril, nifedipine and hydrochlorothiazide. One open,
non-comparative study showed that a significant reduction in BP is maintained over 1 year.
It is properly tolerated; the frequency and severity of adverse events is
similar to that reported for placebo, atenolol or enalapril in published studies. Within the
largest comparative research the numbers of patients complaining of tiredness was smaller for
nebivolol, (bystolic, nebilet, nebil) in contrast with atenolol, although the numbers in both
groups were too small for any significant comparisons to be made. In addition, in single
comparative research with nifedipine or metoprolol, the overall incidence of adverse events was
smaller in the nebivolol, (bystolic, nebilet, nebil) groups.
Though uncontrolled Left Ventricular failure is listed as a contra-indication
within the SPC, preliminary research have proven that nebivolol has helpful effects on left
ventricular function in individuals with hypertension and heart failure.
Nebivolol is considerably more expensive than blockium, but prices less than
carvedilol or celiprolol.
Nebivolol, (bystolic, nebilet, nebil) has been studied in over 3000 patients
with hypertension, who've received the drug for at the least one month, and a few for 3 years .
Probably the most frequent adverse events (incidence between 1-10%) have been headache, dizziness,
tiredness and paraesthesia. Additional adverse events reported by at least 1% of patients had been:
diarrhoea, constipation, nausea, dyspnoea and oedema . Additional adverse events have been reported
with a frequency of less than 1% of patients of high blood pressure.